Approach to Dyspnea

Initial Assessment and Diagnosis

The American Thoracic Society recommends that the initial focus in managing any patient with dyspnea must be optimizing treatment of the underlying disease, whether that means bronchodilators and corticosteroids for asthma/COPD, diuretics and afterload reduction for heart failure, or antibiotics for pneumonia, before considering symptomatic management of breathlessness itself 1
The World Journal of Emergency Surgery suggests that medication history, particularly drugs with psychoactive properties, such as benzodiazepines, opioids, and anticholinergics, may contribute to respiratory symptoms and should be elicited during the evaluation 2
Critical physical examination findings, including cardiac murmurs, extra heart sounds, irregular rhythm, and peripheral edema, can indicate underlying cardiac or pulmonary disease and should be assessed 3
The use of accessory respiratory muscles, nasal flaring, tachypnea, paradoxical breathing, and fearful facial expression can indicate respiratory distress and should be evaluated 2, 4

The American College of Chest Physicians recommends that obstructive airway disease be treated with optimized inhaled bronchodilator regimens, inhaled corticosteroids for persistent inflammation, and systemic corticosteroids and antibiotics for acute exacerbations 1, 3
The American Heart Association suggests that heart failure be treated with diuretics for volume overload, afterload reduction, beta-blockers, and aldosterone antagonists for systolic dysfunction 1, 3, 5

The American Journal of Respiratory and Critical Care Medicine recommends that non-pharmacological interventions, such as optimal positioning, cool air directed at the face, and environmental modifications, be implemented as first-line therapy for symptomatic relief of dyspnea 1, 2, 8
The World Journal of Emergency Surgery suggests that opioids be used as first-line pharmacological therapy for refractory dyspnea, with dosing regimens tailored to individual patient needs 1, 9, 10
The Journal of the National Comprehensive Cancer Network recommends that benzodiazepines be used as second-line adjunctive therapy for dyspnea, particularly when anxiety or fear contributes to respiratory distress 2, 8, 4

The American Thoracic Society suggests that noninvasive ventilation, such as CPAP or BiPAP, be used only in predisposed settings with trained medical staff, and only until adequate sedation is achieved or when sedation is inadequate 2, 4
The American Journal of Respiratory and Critical Care Medicine recommends that time-limited trials of high-flow nasal cannula, BiPAP, or mechanical ventilation be considered for severe reversible conditions or persistent dyspnea with hypoxemia 8, 3, 5

The Journal of the National Comprehensive Cancer Network recommends that glycopyrrolate be used as the preferred agent for managing excessive secretions contributing to dyspnea, due to its low delirium risk and effectiveness 8
The World Journal of Emergency Surgery suggests that scopolamine, atropine, or hyoscyamine be used as alternative options for managing secretions, with consideration of individual patient needs and potential side effects 5, 8, 4